Asset profile
Defactinib
Small molecule
Evidence outlook
Approved: Ovarian Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
13 competitors in this universe: 0 direct rivals (same mechanism and indication), 1 same-class, 12 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Defactinib: this drug | Approved | Small molecule | FAK | ||
| IN10018 | Phase 3 | Small molecule | FAK | ||
| Avutometinib | Approved | Small molecule | RAF/MEK, MEK1/2 and RAF (CRAF, BRAF) | ||
| Niraparib | Approved | Small molecule | PARP1/2 | ||
| Relacorilant (Lifyorli) | Approved | Small molecule | Glucocorticoid receptor | ||
| INCB123667 | Phase 3 | Small molecule | — | ||
| Olvimulogene Nanivacirepvec | Phase 3 | Oncolytic Virus | No discrete molecular target | ||
| Rina-S | Phase 3 | Small molecule | Folate receptor alpha (FRα) | ||
| Luveltamab Tazevibulin | Phase 2/3 | Antibody–drug conjugate | — | ||
| Birinapant | Phase 2 | — | — | ||
| Stenoparib | Phase 2 | Small molecule | — | ||
| COM701 | Phase 1 | Small molecule | — | ||
| IDE-161 | Phase 1 | Small molecule | PARG | ||
| XmAb541 | Phase 1 | Multispecific antibody | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(17 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2027 (6)
March 2027 (1)
What to watch
April 2027 (1)
What to watch
August 2027 (2)
December 2027 (2)
What to watch
What to watch
2028 (5)
January 2028 (1)
What to watch
August 2028 (1)
What to watch
October 2028 (1)
What to watch
2029 (3)
February 2029 (1)
What to watch
March 2029 (1)
What to watch
September 2029 (1)
What to watch
2030 (1)
April 2030 (1)
What to watch
2031 (1)
January 2031 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.